DCAT Launches Member Survey on Business Continuity Planning after COVID-19

Robbinsville, New Jersey November 10, 2020 — The DCAT Research & Benchmarking Committee launched a benchmarking survey, Lessons and Challenges for Business Continuity Planning: Preparing for the next crisis. The purpose of the survey is to gather the experience and insights of DCAT member pharma companies and suppliers in maintaining operations during the COVID-19 pandemic and in planning for business continuity in the event of future operational and supply disruptions. The survey will be fielded through the fall of 2020 and the results will be made available to DCAT member companies in March 2021.

With a membership consisting of both pharmaceutical companies and their suppliers, the DCAT organization is well positioned to gather and exchange best practices and insights into the management of pharmaceutical supply chains. To learn more about the survey and how your company can participate, visit…

About DCAT

The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing. With over 400 corporate members, DCAT is headquartered in Robbinsville, New Jersey.